Inhibikase Therapeutics, Inc. Revenue
Inhibikase Therapeutics, Inc. (IKT) reported Revenue of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-11
- Inhibikase Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $0.00.
- Inhibikase Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $0.00.
- Inhibikase Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $0.00.
- Inhibikase Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $0.00.
- Inhibikase Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Inhibikase Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $260.50K, a 111.03% increase from fiscal 2022.
- Inhibikase Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $123.44K, a 96.02% decline from fiscal 2021.
- Inhibikase Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $3.10M, a 343.92% increase from fiscal 2020.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2026-08-11 | $0.00 10-Q · filed 2025-11-14 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $0.00 derived: sum of 3 quarters · filed 2026-05-12 | $0.00 derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 derived: sum of 3 quarters · filed 2025-11-14 | $0.00 10-K · filed 2025-03-27 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | $1.00 derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | $1.00 derived: sum of 3 quarters · filed 2025-08-14 | $79.57K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | $1.00 derived: sum of 2 quarters · filed 2025-05-14 | $79.57K derived: sum of 3 quarters · filed 2025-05-14 | $195.98K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $79.57K derived: sum of 2 quarters · filed 2025-03-27 | $195.98K derived: sum of 3 quarters · filed 2025-03-27 | $260.50K 10-K · filed 2025-03-27 |
| 2023-09-30 | $79.57K 10-Q · filed 2023-11-14 | $195.98K derived: sum of 2 quarters · filed 2023-11-14 | $260.50K 10-Q · filed 2023-11-14 | $324.07K derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-06-30 | $116.41K 10-Q · filed 2023-08-14 | $180.93K 10-Q · filed 2023-08-14 | $244.50K derived: sum of 3 quarters · filed 2024-05-15 | $251.79K derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-03-31 | $64.52K 10-Q · filed 2024-05-15 | $128.09K derived: sum of 2 quarters · filed 2024-05-15 | $135.38K derived: sum of 3 quarters · filed 2024-05-15 | $141.93K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $63.57K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $70.86K derived: sum of 2 quarters · filed 2024-03-27 | $77.41K derived: sum of 3 quarters · filed 2024-03-27 | $123.44K 10-K · filed 2024-03-27 |
| 2022-09-30 | $7.29K 10-Q · filed 2023-11-14 | $13.84K derived: sum of 2 quarters · filed 2023-11-14 | $59.87K 10-Q · filed 2023-11-14 | $61.82K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $6.55K 10-Q · filed 2023-08-14 | $52.58K 10-Q · filed 2023-08-14 | $54.53K derived: sum of 3 quarters · filed 2023-08-14 | $382.99K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $46.03K 10-Q · filed 2023-05-15 | $47.98K derived: sum of 2 quarters · filed 2023-05-15 | $376.43K derived: sum of 3 quarters · filed 2023-05-15 | $1.74M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $1.94K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $330.40K derived: sum of 2 quarters · filed 2023-03-31 | $1.69M derived: sum of 3 quarters · filed 2023-03-31 | $3.10M 10-K · filed 2023-03-31 |
| 2021-09-30 | $328.46K 10-Q · filed 2022-11-14 | $1.69M derived: sum of 2 quarters · filed 2022-11-14 | $3.10M 10-Q · filed 2022-11-14 | $3.27M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $1.36M 10-Q · filed 2022-08-12 | $2.77M 10-Q · filed 2022-08-12 | $2.94M derived: sum of 3 quarters · filed 2022-08-12 | $2.98M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $1.41M 10-Q · filed 2022-05-16 | $1.58M derived: sum of 2 quarters · filed 2022-05-16 | $1.62M derived: sum of 3 quarters · filed 2022-05-16 | $1.83M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $170.42K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $208.10K derived: sum of 2 quarters · filed 2022-03-31 | $427.68K derived: sum of 3 quarters · filed 2022-03-31 | $698.47K 10-K · filed 2022-03-31 |
| 2020-09-30 | $37.68K 10-Q · filed 2021-11-15 | $257.26K derived: sum of 2 quarters · filed 2021-11-15 | $528.05K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $219.59K 10-Q · filed 2021-08-16 | $490.37K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $270.79K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |